Selective Serotonin Reuptake Inhibitors (SSRIs), Childhood and Adolescent Depression, and Suicidality Following the FDA's 2004 Black Box Warning: A Systematized Literature Review

Major depressive disorder (MDD) in adolescents is a significant public health concern. When left untreated, it can lead to poor academic performance, substance use, and a heightened risk of suicide. The U.S. Food and Drug Administration (FDA) issued a black box warning on selective serotonin reuptake inhibitors (SSRIs) for patients under 18 due to concerns about increased suicidality - a decision that remains debated given SSRIs' role as first-line treatment for depression and the inherent suicide risk of untreated MDD. This systematized literature review examined the current evidence on the association between SSRI use and suicidality in adolescents with MDD following the FDA black box warning. Following a comprehensive PubMed search, studies were selected using predefined inclusion and exclusion criteria. Eight studies were selected for further data extraction and synthesis. Overall, observational studies found a small but measurable increase in suicidal risk with SSRI use, particularly during the early treatment phase, highlighting the need for close monitoring. Two randomized controlled trials (RCTs) reported increased treatment-emergent suicidality with SSRI monotherapy compared to cognitive behavioral therapy (CBT) or combination therapy, while two other RCTs found no significant association. Across studies, combination therapy with SSRIs and CBT tended to yield better outcomes and lower rates of suicidality. Current evidence reveals that SSRI treatment in childhood and adolescent MDD is associated with a small but measurable increase in suicidality, particularly in early treatment, underscoring the need for close clinical monitoring and concurrent psychotherapy. Clinicians are encouraged to monitor closely for suicidality during early treatment and to carefully weigh the benefits of SSRIs against the risks of untreated depression.

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-12-30
DOI
https://doi.org/10.7759/cureus.100438
Primary Topic
Suicide and Self-Harm Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Selective Serotonin Reuptake Inhibitors (SSRIs), Childhood and Adolescent Depression, and Suicidality Following the FDA's 2004 Black Box Warning: A Systematized Literature Review

Aksha Memon, Harlin Kaur
Cureus
Suicide and Self-Harm Studies
article

Selective Serotonin Reuptake Inhibitors (SSRIs), Childhood and Adolescent Depression, and Suicidality Following the FDA's 2004 Black Box Warning: A Systematized Literature Review

Aksha Memon, Harlin Kaur
article en

Abstract

Major depressive disorder (MDD) in adolescents is a significant public health concern. When left untreated, it can lead to poor academic performance, substance use, and a heightened risk of suicide. The U.S. Food and Drug Administration (FDA) issued a black box warning on selective serotonin reuptake inhibitors (SSRIs) for patients under 18 due to concerns about increased suicidality - a decision that remains debated given SSRIs' role as first-line treatment for depression and the inherent suicide risk of untreated MDD. This systematized literature review examined the current evidence on the association between SSRI use and suicidality in adolescents with MDD following the FDA black box warning. Following a comprehensive PubMed search, studies were selected using predefined inclusion and exclusion criteria. Eight studies were selected for further data extraction and synthesis. Overall, observational studies found a small but measurable increase in suicidal risk with SSRI use, particularly during the early treatment phase, highlighting the need for close monitoring. Two randomized controlled trials (RCTs) reported increased treatment-emergent suicidality with SSRI monotherapy compared to cognitive behavioral therapy (CBT) or combination therapy, while two other RCTs found no significant association. Across studies, combination therapy with SSRIs and CBT tended to yield better outcomes and lower rates of suicidality. Current evidence reveals that SSRI treatment in childhood and adolescent MDD is associated with a small but measurable increase in suicidality, particularly in early treatment, underscoring the need for close clinical monitoring and concurrent psychotherapy. Clinicians are encouraged to monitor closely for suicidality during early treatment and to carefully weigh the benefits of SSRIs against the risks of untreated depression.

CureusVol. 17(12)
Creighton University (US)
Openalex Percentile: Top 26%
Suicide and Self-Harm Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.